FGFR4 and metabolic disease: In this study, tylosin TMDI-treated mice showed increased PBA/SBA ratios and lower FGF15 levels in the ileum and portal vein, thereby decreasing the expression of hepatic FGFR4, which may cause metabolic disorders by affecting metabolism-related signaling pathways in the liver (46, –, 48).